Galapagos NV (LTS:0JXZ)
€ 25.37 -0.57 (-2.2%) Market Cap: 1.69 Bil Enterprise Value: -1.64 Bil PE Ratio: 8.16 PB Ratio: 0.59 GF Score: 54/100

Galapagos NV R&D Update 2019 Transcript

Nov 14, 2019 / 01:00PM GMT
Release Date Price: €166.3 (-3.82%)
Elizabeth Goodwin
Galapagos NV - VP of IR

Thank you all for joining the Galapagos team for the 10th Annual R&D Update Event at Galapagos.

This is Elizabeth Goodwin speaking. I'm Vice President, Investor Relations. And I'm joined here in New York by Sofie Van Gijsel, Bart Filius, Walid Abi-Saab, Piet Wigerinck and about 100 investors and bankers.

This year's R&D update marks an important inflection point for the company as we stand at the cusp of our commercial phase with filgotinib, while embarking on an exciting new R&D collaboration with Gilead.

But before we begin, I do need to take care of a few logistics. You can find the webcast player via link on our homepage. And for those who'd like to join by telephone, please find the dial-in numbers and code on our homepage. A replay of this presentation will be available on our website later today and we'll provide a reviewed transcript on our site in the course of next week.

I need to start by reminding you that we'll be making forward-looking statements today. Actual results may differ from these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot